BiotechnologyThymmune Therapeutics Receives $37M in Funding from the National Institutes of Health’s Advanced Research Projects Agency for Health (ARPA-H)
Thymmune Therapeutics, a biotechnology company developing scalable thymic cell therapies to restore immune function in aging and disease, today announced that the U.S. Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H) has awarded up to $37 million in funding to the Thymus Rejuvenation project. This is the first industry project funded by the ARPA-H Open Broad Agency Announcement. The Thymus Rejuvenation project, led by Thymmune Therapeutics, aims to restore...